The cards are certainly stacked against this biotech stock. But if its experimental lead drug proves effective, the sky could be the limit.
News & Analysis: Oncolytics Biotech, Inc.
Oncolytics announces successful tests for cancer drug Reolysin.
Andrew W. Lo from the MIT Sloan School of Management has a rather Foolish idea for solving the world's biggest problems.
These stocks just rolled over. Can they come back?
A look back at the biggest stories this week in biotech and what they mean for investors.
Some of the sector's big movers.
Reolysin has already advanced into a phase 2 trial in colorectal cancer.
Can investors reap rewards from Oncolytics Biotech's cancer-killing virus?
Market-lagging returns could be written in this 1-Star.
Our investing community's latest prime pick to avoid: Oncolytics Biotech.